BETHESDA, Md., May 4, 2016 -- The Bladder Cancer Advocacy Network is pleased to announce the appointment of Andrea Maddox-Smith as Chief Executive Officer, effective May 2.
Maddox-Smith is an innovative and energetic leader with extensive experience in non-profit management, program development and fundraising. Prior to joining BCAN, Maddox-Smith served in a variety of leadership roles at the American Diabetes Association for 16 years, most recently as the senior vice president, Eastern division/nationwide mission delivery. In this role, she oversaw all aspects of operations management, new business development, staff management and volunteer recruitment.
"We are thrilled to have Andrea on board," said Diane Zipursky Quale, co-Founder of BCAN. "We know that she will inspire the bladder cancer community and marshal the people and resources necessary to collaboratively implement BCAN's mission and ensure the organization's continued growth and impact."
The new leadership comes at a critical time in the organization's history with the recent introduction of the Bladder Cancer Genomics Consortium. A collaboration with BCAN and major medical institutions, the consortium is designed to increase research to improve outcomes for bladder cancer patients.
"I strive to create a sense of urgency around this disease that would allow every newly diagnosed bladder cancer patient access to BCAN resources," said Maddox-Smith. "I am excited to bring a progressive and results oriented approach and vision to the organization by collaborating with the many volunteers, researchers, clinicians and members."
About the Bladder Cancer Advocacy Network
The Bladder Cancer Advocacy Network's mission is to increase public awareness about bladder cancer, advance bladder cancer research, and provide educational and support services for the bladder cancer community. BCAN serves as the leading voice for bladder cancer in the U.S., providing resources to not only those diagnosed with the disease but their families, caregivers and the medical community united in support of people impacted by the disease. The organization is setting the agenda for bladder cancer by promoting and funding collaborative and cutting-edge research programs and providing critical patient support and education services. BCAN works collaboratively with the medical and research professionals dedicated to the prevention, diagnosis, and treatment of bladder cancer, and empowers the patient community by allowing them to share experiences with others and to participate in building awareness of the need for a cure. For more information go to www.bcan.org or call 1-888-901-BCAN (2226).
CONTACT: Natalie Bennett
Email: [email protected]
Phone: 301.215.9099 ext 202


FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Italy Fines Apple €98.6 Million Over App Store Dominance
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 



